Patent intelligence · US
US 10246707
Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
Patent details — US 10246707
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 2, 2019
- Expiration
- Mar 28, 2039
- Applicant
- BIOMARIN TECHNOLOGIES B.V.
- Claims
- 12
- CPC classes
- A61K, A61K48/00, A61P, A61P21/00
Quick answer
US 10246707 (Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means) is held by BIOMARIN TECHNOLOGIES B.V.. Status: granted. Granted Apr 2, 2019. Expires Mar 28, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOMARIN TECHNOLOGIES B.V.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K48/00, A61P, A61P21/00, A61P21/04, A61P43/00
More from BIOMARIN TECHNOLOGIES B.V.
Related pharmaceutical patents in our USPTO index.
-
US 12427171
Krill oil composition enriched in LPC-DHA and LPC-EPA
granted -
US 12331293
Bispecific antisense oligonucleotides for dystrophin exon skipping
granted -
US 12239692
Adeno-associated virus factor VIII vectors
granted -
US 12233106
C-type natriuretic peptide variants to treat skeletal dysplasia in children
granted -
US 12214015
Use of c-type natriuretic peptide variants to treat osteoarthritis
granted -
US 12194064
Process of producing concentrated therapeutic phospholipid composition from krill extracts containing high level of free fatty acids
granted -
US 12188058
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
granted -
US 12076372
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
granted
Frequently asked questions
What is US patent 10246707?
US 10246707 (Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means) is held by BIOMARIN TECHNOLOGIES B.V.. Status: granted. Granted Apr 2, 2019. Expires Mar 28, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10246707?
BIOMARIN TECHNOLOGIES B.V. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 175 pharmaceutical patents for this assignee.
When does US 10246707 expire?
Our index shows an expiration date of Mar 28, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.